Arvinas rules out a solo vepdegestrant launch
If Pfizer hands back the estrogen receptor degrader, Arvinas will seek a new partner.
Arvinas leader departs under a Pfizer-shaped cloud
Weeks after criticising the group’s big pharma partner, John Houston is on his way out.
ASCO 2025 – Astra seeks a new SERD paradigm
But camizestrant’s use could depend on uptake of monitoring – for now.
ASCO 2025 – vepdegestrant matches rival degraders
Any hopes of differentiation could come down to side effects.
The month ahead: June’s upcoming events
Crunch time approaches for UroGen.
The month ahead: May’s remaining events
Conference activity picks up, with the big one – ASCO – at the end of the month.
Vepdegestrant’s promise narrows
Arvinas and Pfizer abandon first-line atirmociclib combo plans only disclosed in January.
Arvinas’s degrader disappoints
The Pfizer-partnered vepdegestrant shows a benefit in ESR1 mutants, but not in all-comers.
Will Roche's Perseverance pay off?
Giredestrant will soon become the first oral SERD to yield first-line data.